Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Lymphoma, T-Cell, Peripheral 4Lymphoma 4Lymphoma, T-Cell 3Prostatic Neoplasms 2Neoplasm Metastasis 2Hematologic Neoplasms 2Carcinoma, Renal Cell 2Recurrence 1Pancreatic Neoplasms 1Neoplasms 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1

Interventions

pembrolizumab 80Nivolumab 60Sunitinib 59Sorafenib 36Everolimus 32pazopanib 30Axitinib 27cabozantinib 25Ipilimumab 24Bevacizumab 24atezolizumab 20belzutifan 19lenvatinib 16avelumab 13Paclitaxel 10Docetaxel 9temsirolimus 8Cyclophosphamide 8spartalizumab 7fludarabine 7Interleukin-2 7Interferon alpha-2 7tivozanib 6durvalumab 6Cetuximab 6cemiplimab 5aldesleukin 5Ramucirumab 5CB-839 5bempegaldesleukin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Renal Cell × romidepsin × Clear all
NCT00106301 2019-11-18

Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228

Celgene

Phase 2 Completed
2 enrolled
Genitourinary

Carcinoma, Renal Cell, Prostatic Neoplasms

NCT00106613 2019-10-18

A Research Study for Patients With Metastatic Renal Cell Carcinoma

Celgene

Phase 2 Completed
30 enrolled
Genitourinary

Carcinoma, Renal Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡